Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    20956803 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Conditions: Lymphoma, Mantle Cell;   Mantle Cell Lymphoma
Interventions: Drug: Rituximab (R);   Biological: EPOCH;   Drug: Bortezomib (B);   Drug: Bortezomib;   Drug: Bortezomib or observation

Study has passed its completion date and status has not been verified in more than two years.